The combination drugs debate: Incompatibility problems can be overcome - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The combination drugs debate: Incompatibility problems can be overcome


Pharmaceutical Technology Europe
Volume 21, Issue 9

For an alternative view on combination drugs, go to http://www.pharmtech.com/unstable


(David Gould/Getty Images)
With declining numbers of new chemical entities (NCEs), there is a new-found aggression for developing differentiated products using currently approved drugs. Fixed drug combination products have emerged as a differentiation strategy, as is evident by the increasing number of such product approvals1 and recent launches. The strategy involves identifying molecules that, when combined, will lead to an improved therapeutic outcome compared with other treatment options. The rationale for such products are the associated advantages, such as improved patient compliance, complementary pharmacodynamic effect and improved bioavailability. Product stability, however, is a common and significant factor affecting the outcome of the product development project.

What are the stability issues?

Stability problems in combination products can be attributed to three types of interaction:
  • Drug–drug chemical interaction: two or more drugs interact directly, resulting in drug degradation and a number of impurities; for example, lisinopril combined with aspirin undergoes acetylation to generate acetyl lisinopril,2 which could lead to a number of possible adverse events.
  • Drug–excipient interaction: a drug in a combination product has an excipient that is incompatible with other drugs; for example, telmisartan in a telmisartan-hydrochlorothiazide combination product needs the incorporation of an alkaline excipient. Hydrochlorothiazide, however, degrades in an alkaline environment.3
  • Drug–excipient–drug interaction: occasionally, combination drugs, which may not be interacting directly, exhibit incompatibility in the presence of certain formulation components; for example, the combination of rifampicin and isoniazide is stable unless there is any excipient or agent that creates an acidic or alkaline environment.4

The incompatibility interactions are often facilitated by the close contact between drugs and excipients. There are other factors such as the pH of the formulation microenvironment, temperature and moisture — all of which initiate and catalyse chemical reactions.

The instability of combination drugs is manifested in various forms that can be broadly classified into three groups: physical instability, which includes changes in physical appearance (e.g., colour, precipitation, hardness, etc.); chemical instability — variation in drug content and impurities; and functional instability — changes in the drug release pattern.

We can address incompatibility challenges

Significant research has been conducted to understand the root cause of drug incompatibility issues. The vast amount of literature and knowledge on the structural and chemical properties of drugs and excipients can help development teams to assess possible incompatibilities and make a development strategy that addresses such challenges effectively.

As previously mentioned, the instability of combination products is mainly the result of incompatibility between formulation components; for example, drug and excipients. A systematic development strategy is the first step to detect any potential compatibility issues and accordingly design the product. It is, therefore, possible, to safely develop a combination drug product that is stable and has a sufficient shelf-life, so long as the following key factors are considered: preformulation and degradation; dosage form selection; packaging development; preclinical studies; and product specification.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here